Gene editing companies are bucking the downturn in funding, with Tune Therapeutics recently securing $175 million. The financing round is expected to help bring epigenetic editing technology to clinical trials. This move contrasts with the recent layoffs and pipeline cuts seen in genetic medicine.
Source: https://endpts.com/tune-therapeutics-raises-175m-series-b-for-epigenetic-editing